News Image

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

Provided By PR Newswire

Last update: Aug 13, 2025

Processed 2,756 EsoGuard® tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones

Read more at prnewswire.com

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (8/27/2025, 8:02:00 PM)

After market: 1.29 +0.03 (+2.38%)

1.26

+0.08 (+6.78%)

PAVMED INC

NASDAQ:PAVM (8/27/2025, 8:11:05 PM)

After market: 0.492 +0.01 (+2.07%)

0.482

-0.04 (-7.13%)


Find more stocks in the Stock Screener

LUCD Latest News and Analysis

15 days ago - By: Chartmill
News Image
Follow ChartMill for more